DPP4 and diabetes mellitus: Overall in English practices, between 1 March and 10 December 2020, the overall rate of prescribing new diabetes medications was reduced by 19% (95% CI: 15% to 22%) when compared with historical trends (table 1); the most affected medication being dipeptidyl peptidase-4 inhibitors (reduction (95% CI): 34% (29% to 39%)) and the least affected being insulin which was initiated more frequently during this period compared with historical trends (increase (95% CI): 18% (10% to 26%)).